Thyroid Cancer Treatment in India and UAE | Complete Patient Guide

• Confirmed thyroid nodule(s) with fine-needle aspiration cytology (FNAC) reported as Bethesda Category V (suspicious for malignancy) or VI (malignant)

• Histopathologically proven PTC, FTC, Hurthle cell carcinoma, MTC, or ATC on core needle biopsy or post-lobectomy pathology

• Patients with compressive symptoms: progressive dysphagia, stridor, voice hoarseness, or superior vena cava syndrome from a large thyroid mass

• MEN2 syndrome carriers or RET mutation-positive individuals (germline testing recommended before prophylactic thyroidectomy)

• Recurrent or metastatic DTC progressing on or ineligible for RAI therapy, requiring multikinase inhibitor initiation

• Structural recurrence detected on neck ultrasound, CT chest/neck with contrast, or 18F-FDG PET-CT

Required Diagnostics (pre-treatment work-up):

• High-resolution neck ultrasound with nodule mapping (ACR TIRADS or ATA classification)

• Fine-needle aspiration cytology (FNAC) with or without BRAF/RAS/RET molecular testing (ThyroSeq v3 or Afirma GSC for indeterminate nodules)

• Serum TSH, Free T3, Free T4, Anti-TPO, Anti-Tg antibodies

• Serum calcitonin and CEA (mandatory if MTC suspected)

• Serum calcium, PTH, and Vitamin D (parathyroid baseline)

• CT neck and chest with IV contrast or MRI neck (for locoregional staging)

• 18F-FDG PET-CT (recommended for high-risk DTC, MTC, ATC, or suspected distant metastasis)

• Laryngoscopy (vocal cord mobility assessment prior to any thyroid surgery)

• 24-hour urine metanephrines (to exclude concurrent phaeochromocytoma in MEN2 patients before surgery)

• Echocardiography and cardiac clearance for patients aged >60 or with cardiac comorbidities scheduled for general anaesthesia

Contraindications / Special Considerations:

• Uncontrolled coagulopathy (correct prior to surgery; target INR <1.5)

• Active systemic infection requiring resolution before elective surgery

• Severe cardiopulmonary disease with ASA Class IV–V risk (requires multidisciplinary optimisation)

• Pregnancy (RAI absolutely contraindicated; surgery ideally deferred to second trimester)

• Documented hypersensitivity to lenvatinib, sorafenib, or cabozantinib in patients requiring systemic therapy (alternative agent selection required)

• Prior high-dose neck irradiation (increases surgical complexity; mandates experienced head-and-neck oncology surgeon)

Thyroid cancer treatment is subtype-specific and stage-dependent. The following modalities are deployed individually or in multimodal combination:

1. SURGICAL APPROACHES

Total Thyroidectomy (TT): The cornerstone of treatment for tumours >1 cm, bilateral disease, extrathyroidal extension, or any MTC/ATC. Performed under general anaesthesia via a low cervical collar incision (Kocher incision). Intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN) is standard at high-volume centres. Parathyroid identification and autotransplantation are performed to minimise post-operative hypoparathyroidism.

Hemithyroidectomy / Thyroid Lobectomy: Appropriate for confirmed low-risk PTC ≤4 cm confined to one lobe without nodal involvement, per ATA 2015 guidelines. Reduces lifelong levothyroxine dependency risk while maintaining curative intent.

Central Compartment Neck Dissection (Level VI): Prophylactic central neck dissection is recommended for MTC and high-risk PTC; therapeutic dissection is performed for clinically node-positive disease.

Lateral Neck Dissection (Levels II–V): Indicated for biopsy-confirmed lateral compartment nodal metastases; selective rather than radical dissection is preferred to reduce morbidity.

Remote Access / Robotic-Assisted Thyroidectomy: Increasingly available at tertiary Indian and UAE centres. Techniques include the Transaxillary Robotic Thyroidectomy (TART), Bilateral Axillo-Breast Approach (BABA), and Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA). These eliminate the cervical scar entirely, with equivalent oncological outcomes for appropriately selected patients (tumour ≤2 cm, BMI <30, no prior neck surgery). The da Vinci Surgical System is utilised at multiple JCI-accredited partner hospitals in India (Apollo, Fortis, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai).

2. RADIOACTIVE IODINE (RAI / I-131) THERAPY

Post-operative RAI remnant ablation is indicated for intermediate-to-high-risk DTC. The patient undergoes either levothyroxine withdrawal (raising endogenous TSH to >30 mIU/L) or recombinant human TSH (rhTSH, Thyrogen) stimulation to maximise iodine uptake. Administered activities range from 30–150 mCi for remnant ablation to 100–200+ mCi for adjuvant treatment of metastatic disease. A post-therapy whole-body scan at 5–7 days identifies occult metastases. Patients are isolated per radiation safety protocols for 24–72 hours post-administration.

3. TARGETED MOLECULAR THERAPIES (SYSTEMIC)

• RAI-Refractory DTC: Lenvatinib (Lenvima, 24 mg/day) is first-line with a median PFS of 18.3 months (SELECT trial). Sorafenib (Nexavar, 400 mg BID) is an alternative. Cabozantinib (Cabometyx) is approved as second-line post-lenvatinib progression (COSMIC-311 trial).

• BRAF V600E-Mutant PTC (advanced/ATC): Dabrafenib (150 mg BID) plus trametinib (2 mg/day) — the only FDA-approved regimen for BRAF V600E-mutant ATC, with an overall response rate of 56% and disease control rate of 69% (BRAFi/MEKi combination).

• MTC (progressive/metastatic): Vandetanib (Caprelsa, 300 mg/day) or cabozantinib (Cometriq, 140 mg/day) — both RET/VEGFR kinase inhibitors with FDA approval. The selective RET inhibitor selpercatinib (Retevmo) is indicated for RET mutation-positive MTC with superior selectivity and tolerability.

• RET Fusion-Positive PTC: Selpercatinib and pralsetinib (Gavreto) — next-generation RET-selective inhibitors with response rates exceeding 60% in RET fusion-positive thyroid cancer.

• NTRK Fusion-Positive Thyroid Cancer: Larotrectinib (Vitrakvi) or entrectinib — tumour-agnostic TRK inhibitors.

4. EXTERNAL BEAM RADIOTHERAPY (EBRT)

Used for ATC (concurrent with platinum-based chemotherapy, typically weekly paclitaxel or docetaxel), post-operative high-risk DTC with gross residual disease, and for palliative bone or brain metastases. Intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) minimise dose to adjacent critical structures (spinal cord, oesophagus, salivary glands). Stereotactic body radiotherapy (SBRT) is used for oligometastatic disease.

5. ACTIVE SURVEILLANCE (LOW-RISK MICRO-PTC)

For incidentally detected papillary microcarcinomas (≤1 cm, no ETE, no nodal disease), active surveillance with serial ultrasound every 6–12 months is an evidence-based alternative to immediate surgery in carefully selected, informed patients — a protocol pioneered at Kuma Hospital (Japan) and adopted by major international guidelines.

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel)

• GAF Healthcare case manager reviews uploaded medical records, biopsy reports, ultrasound images, and prior treatment history.

• Multidisciplinary tumour board (endocrine surgeon, nuclear medicine physician, medical oncologist, endocrinologist) at the partner hospital reviews the case and formulates a personalised treatment plan.

• Patient receives a detailed cost estimate, treatment protocol summary, and hospital admission confirmation.

• E-Medical Visa application (India) or entry visa assistance (UAE) initiated by GAF Healthcare.

• Pre-operative laboratory work (CBC, metabolic panel, coagulation, thyroid function, calcitonin, PTH) and any outstanding imaging (PET-CT, CT contrast) arranged on Day 1–2 of arrival.

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 1–3)

• Airport pickup by GAF Healthcare ground coordinator.

• Day 1: Hotel check-in; orientation briefing.

• Day 2: Hospital pre-admission — anaesthesiology consultation, cardiology clearance if required, laryngoscopy (vocal cord baseline), IONM baseline testing.

• Day 3: Endocrine surgeon consultation, surgical consent, bowel prep and pre-operative fasting instructions. For patients undergoing RAI therapy only (non-surgical), low-iodine diet initiated 2 weeks before RAI; rhTSH (Thyrogen) injections on Days 1–2.

PHASE 3 — SURGICAL PROCEDURE (Day 3 or 4)

• Total thyroidectomy ± central/lateral neck dissection performed under general anaesthesia; duration 2–4 hours depending on extent of dissection.

• Robotic-assisted (TOETVA or TART) cases: Duration 3–5 hours; surgeon operates via da Vinci console.

• Intraoperative recurrent laryngeal nerve monitoring (IONM) maintained throughout.

• Parathyroid glands identified; devascularised glands autotransplanted to sternocleidomastoid muscle.

• Frozen section analysis available intra-operatively for margin assessment.

• Jackson-Pratt drain placed; patient moved to recovery and monitored for airway patency, haematoma, and hypocalcaemia (calcium and PTH checked at 4 hours and 24 hours post-op).

PHASE 4 — HOSPITAL RECOVERY (Day 4–7)

• Drain removal at 24–48 hours if output <30 mL/day.

• Serum calcium and intact PTH monitoring; oral calcium carbonate and calcitriol initiated prophylactically.

• Voice assessment by speech therapist on Day 2 post-op.

• Levothyroxine suppression therapy initiated (TSH target <0.1 mIU/L for high-risk, 0.1–0.5 for low-risk).

• Wound care education; sutures or surgical glue assessed for integrity.

• Pathology report reviewed at Day 5–7 with oncologist; RAI scheduling confirmed if indicated.

• Discharge on Day 4–7 post-surgery.

PHASE 5 — POST-DISCHARGE RECOVERY IN DESTINATION (Week 2–4)

• Patient stays at GAF Healthcare partner accommodation near the hospital.

• RAI therapy (if planned): Administered Week 3–4 post-surgery after TSH stimulation. Patient isolated for 24–72 hours. Post-therapy whole-body scan performed at Day 5–7 post-RAI.

• Follow-up clinic visit at Week 2 (wound check, calcium optimisation, levothyroxine dose titration).

• Molecular therapy initiation (lenvatinib, selpercatinib, etc.) reviewed and prescribed if systemic therapy is part of the plan; first cycle tolerance assessed.

• Nutritional counselling, iodine restriction guidance, and radiation safety instructions provided.

PHASE 6 — FIT TO FLY & REPATRIATION (Week 3–4 post-surgery; Week 5–6 if RAI included)

• Radiation safety clearance issued by nuclear medicine physician (mandatory before air travel post-RAI).

• Final discharge summary, histopathology report, post-therapy scan images, and medication list prepared in English and, where applicable, the patient's native language.

• GAF Healthcare coordinates airport transfer and provides 24-hour teleconsultation access for the first 12 weeks after return home.

• Long-term follow-up protocol: Serum thyroglobulin + anti-Tg antibody at 3, 6, and 12 months; neck ultrasound at 6 and 12 months; whole-body scan at 6–12 months if RAI was administered.